Background: Large-cell neuroendocrine carcinoma of the lung (LCNEC) is a rare disease with poor prognosis and limited treatment options. Neuroendocrine tumors frequently show overactivation of the mTOR pathway. Based on the good activity of the mTOR inhibitor everolimus in different types of neuroendocrine tumors and the results of a previous phase I trial, we evaluated the efficacy and safety of everolimus in combination with carboplatin and paclitaxel as upfront treatment for patients with advanced LCNEC.
Introduction
Large-cell neuroendocrine lung carcinoma (LCNEC) is a rare (2%-3%) pulmonary neoplasm first described in 1991 [1] . It is distinguished from the more common non-small cell lung cancer (NSCLC) entities by a neuroendocrine differentiation and growth pattern [2] . Furthermore, its high mitotic rate, extensive necrosis, typical genetic alterations [3] and aggressive clinical course [4] distinguish it from low and intermediate grade neuroendocrine tumors (typical and atypical carcinoids) and suggest a close biological relationship with small-cell lung cancer (SCLC). Delineating the histologic diagnosis from small biopsies is challenging and according to the WHO requires not only typical neuroendocrine morphology, like organoid nesting, trabecular growth, rosette-like structures and nuclear palisading, but also a clear positivity for at least one immunohistochemical neuroendocrine marker except NSE, such as chromogranin A, synaptophysin and/or CD56 [2] .
Due to the rarity of patients with LCNEC there are no clinical trials that define the optimal therapy for either localized or advanced disease [5] . Treatment recommendations are based on the approach to either SCLC or other NSCLC and the data of a few published series [4] . Platinum compounds and taxanes have established activity in advanced disease [6, 7] , but the prognosis remains poor with a median overall survival (OS) of 8-12 months [8, 9] . Thus, there is an imperative need for prospective studies of novel compounds [10] .
Everolimus is an oral mTOR inhibitor derived from rapamycin. Its target, the serine/threonine kinase mTORC1, regulates cell proliferation by integrating signals from growth factors, hormones, cytokines, nutrients and cellular stress [11] . This pathway is overactivated in several malignancies [12, 13] , and everolimus is currently approved for the treatment of hormone-resistant breast cancer, tyrosine-kinase-inhibitor-resistant renal cell carcinoma and welldifferentiated neuroendocrine tumors of the pancreas, gastrointestinal tract or lung [14] . On the other hand, everolimus is a potent immunomodulator [15] . Although classically viewed as an immunosuppressant and used to prevent graft rejection after transplantation [16] , recent studies show that mTOR inhibition also enhances CD8 þ T-cell mediated tumor immunity [17] and improves immune function in the elderly [18] . Immunologic factors predict response to chemotherapy [19] and are important for clinical outcome in metastatic NSCLC [20] , as also suggested by the recent success of immune checkpoint inhibitors in the treatment of NSCLC patients [21] . The dual antiproliferative and immunomodulatory activity of everolimus, its special benefit in neuroendocrine neoplasms and the limited therapeutic options in LCNEC served as the rationale for performing this multicenter phase II study. Carboplatin and paclitaxel, both with established activity in LCNEC, SCLC and NSCLC, were combined with everolimus 5 mg daily based on the results of a previous phase I trial [22] .
Methods
This trial was approved by a Research Ethics Board on behalf of Novartis as well as by the Ethics Committee of every participating center. A written informed consent was obtained from every patient at study inclusion.
Recruitment took place in 10 study centers in Germany between April 2011 and March 2015. Eligible patients were adults with a histologically confirmed stage IV LCNEC, a WHO performance status of 0 or 1 and adequate bone marrow, liver and renal function. In accordance with the current WHO recommendation the diagnosis of LCNEC required neuroendocrine morphology, like organoid nesting, trabecular growth, rosette-like structures and nuclear palisading, positivity for at least 1 of the following three markers synaptophysin, chromogranin A, CD56, and an increased proliferation rate with >11 mitoses/10 HPF (plus a Ki67 proliferation rate of >50%, if available) [2, 23] . Minimization of the interobserver variation in a correct application of these criteria in all study centers was enforced by three face-to-face training and harmonization meetings attended by the participating pathologists and principle investigators of each center. Main exclusion criteria were the presence of a clear SCLC morphology, co-medication with steroids corresponding to 10 mg/d methylprednisolone or with drugs affecting the activity of cytochrome enzymes, untreated or symptomatic brain metastases in the 3 months prior to enrollment, another active malignancy in the past 3 years and prior chemotherapy for lung cancer.
All patients received 5 mg everolimus daily plus a 3-h i.v. infusion of paclitaxel 175 mg/m 2 followed by a 30-to 60-min i.v. infusion of carboplatin AUC 5 every 3 weeks for a maximum of four cycles. On day 1 and 12 6 2 of each cycle patients were evaluated and chemotherapy administration would be delayed in case of cytopenia until hematologic recovery (neutrophils >1500/ml, platelets >100 000/ml). In addition, dose reductions of chemotherapy (paclitaxel 135 mg/m 2 and carboplatin AUC 4) and dose reduction (to 5 mg every other day) or interruption (for up to 21 days) of everolimus were allowed for tolerability issues. Patients with at least stable disease after four cycles further received 5 mg everolimus daily until disease progression or unacceptable toxicity.
The primary end point was the proportion of progression-free subjects at month 3. Secondary end points were the proportion of progressionfree subjects at month 6, overall response rate (ORR, complete response
, progression-free survival (PFS) and OS. Computerized tomographies (CT) of the chest and abdomen for tumor assessment were performed every 6 weeks, reviewed centrally and graded using RECIST v1.1 [24] . Signs suggesting disease progression triggered additional investigations at any time. Adverse events (AE) were recorded according to the National Cancer Institute Common Toxicity Criteria (CTCAE v4.0). The study was terminated prematurely in November 2014 due to a low recruitment rate after enrolling 49 patients.
Statistical analysis
The study was planned to reject the tested treatment as ineffective if the proportion of progression-free patients at 3 months was 55% (corresponding to a median PFS of 3.5 months); and retain it if the proportion was 67.5% (corresponding to a median PFS of 5.3 months). Assuming the originally foreseen 71 evaluable subjects, at least 63% progressionfree subjects at 3 months (corresponding to a median PFS of 4.5 months) were required for a target a of 10% and statistical power of 80%. Since this study was discontinued prematurely due to a low recruitment rate, no formal comparison of efficacy measures with the predefined threshold could be performed. Instead, for all efficacy measures exact 95% Clopper-Pearson confidence intervals (CI) were computed.
Only one analysis at the end of the study was performed, based on a cut-off date of May 2015 and including all patients who had received at least one dose of study drug (intention-to-treat [ITT] population). Time-to-event data were analyzed according to Kaplan-Meier. In addition, the proportion of progression-free patients at 3 months (primary end point) is also reported by including censored cases as 'non-progression-free' in the denominator, which was required by the protocol. The correlation of NSE levels with survival was tested using a Cox regression model with NSE level as a covariate.
Results
The study population consisted of 49 patients with a mean age of 62 years and a preponderance of male smokers (Table 1) , including four pretreated cases: one patient after whole-brain radiation therapy for symptomatic brain metastases; one patient after incomplete tumor resection and adjuvant thoracic irradiation; and two patients with disease progression within 3 months of platin-vinorelbine thoracic chemoradiation, who violated the study inclusion criteria. Treatment consisted of four chemotherapy cycles in median combined with a mean daily dose of 4.7 mg everolimus for a mean duration of 3.5 months.
According to the central radiologic assessment the best response was PR in 45% (n ¼ 22) and SD in 29% (n ¼ 14) of patients, which adds up to a DCR of 74% (CI 59%-85%). Seven patients were not evaluable for response due to early withdrawal of informed consent (n ¼ 4) or early death (n ¼ 3). The median follow-up was 91 days for progression and 249 days for survival, the median PFS 132 days (4.4 months, CI 3.2-6 months, Figure 1A ) and the median OS 298 days (9.9 months, CI 6.9-11.7 months, Figure 1B) . The PFS rate at 3 months was 76% (CI 64%-88%) according to KaplanMeier and 49% (CI 34%-64%) with inclusion of censored cases in the denominator (primary end point).
The most frequently observed adverse events were fatigue (22%), diarrhea (22%), anemia (20%), neutropenia (18%) and alopecia (18%, Table 2 ). Grade-3/4 toxicities occurred in 51% of patients and mainly consisted of decline in general health (8%), cytopenias (24%), infections (10%) and gastrointestinal complaints (8%, Table 2 ). No case of severe stomatitis occurred. Treatment interruptions or dose-reductions occurred in 15 (30%) patients, mainly due to cytopenia, infection, respiratory symptoms and decline in general health.
NSE serum levels at baseline were available for 25 patients and were not associated with clinical outcome. However, high levels of minimal induced NSE (defined as the minimal serum NSE level measured during the study) were significantly associated with short PFS and OS (P ¼ 0.0114 and P ¼ 0.0003, respectively).
Discussion
LCNEC is an orphan disease with sparse data from clinical trials to guide treatment. Only platin-based chemotherapies have 15 (30) a One patient with previous whole-brain radiation therapy for symptomatic brain metastases and one after incomplete tumor resection and adjuvant thoracic irradiation. b Two patients had progressive disease within 3 months of platin-vinorelbine thoracic chemoradiation at the time of study inclusion (violation of the study inclusion criteria). and the median OS 298 days (9.9 months, CI 6.9-11.7 months). The PFS rate was 76% at 3 months and 36% at 6 months. The OS rate was 94% at 3 months, 67% at 6 months and 34% at 1 year.
shown significant activity [25] , but outcomes remain poor [4] . Currently actionable genetic alterations, like EGFR mutations or ALK translocations, are rare in this entity [26] , therefore alternative therapeutic strategies are urgently needed. Inhibition of the serine/threonine protein kinase mTOR has proven a valuable therapeutic maneuver in several solid and hematologic malignancies even after failure of standard initial treatment [12] . Since neuroendocrine neoplasms of the lung also feature overactivation of the mTOR pathway [13] , we explored the feasibility and efficacy of everolimus with carboplatin and paclitaxel as first-line treatment of patients with metastatic LCNEC.
With 49 patients the current prospective, multicenter phase II trial is one of the largest clinical studies for this uncommon entity [4] . The enrolled patients represent a typical LCNEC cohort with a mean age of 62 years and a predominance of male (71%) smokers (98%) [27] . Main strengths of the study are the multicenter design, the uniform patient population with stage IV disease and the central radiologic assessment of response. In addition, three face-to-face training and harmonization meetings of participating pathologists were organized to enforce a low interobserver variability in the application of an accurate LCNEC diagnosis across the 10 study centers. Reason was the high interobserver variability of >25% observed in another LCNEC trial, which however did not substantially alter the study results, probably because of the close biologic relationship of LCNEC to the usual alternative diagnosis, namely SCLC [8] .
The ORR was 45%, the median PFS 4.4 months and the median OS 9.9 months. These results are comparable to the findings of other prospective and retrospective LCNEC series, which have observed OR rates of 40%-50%, median PFS intervals of 4-6 months and median OS intervals of 8-12 months with platinum-doublet chemotherapy regimens [6, 8, 9, 28] . Since our study was discontinued prematurely due to a low recruitment rate, no formal comparison of efficacy measures with the predefined threshold was performed. Let it be noted, however, that we observed a high PFS rate of 76% at 3 months and that the observed DCR of 74% in our study compares favorably with the predefined end point in a French prospective phase II study of 42 stage IIIB/IV LCNEC patients treated with cisplatin/etoposide, which aimed for a DCR of 50% [8] . The poor prognosis of stage IV LCNEC patients was recently also emphasized in a retrospective analysis from the population-based Netherlands Cancer Registry, which showed a median OS of only 4.0 months in general and 7.7 months after chemotherapy [27] . Considering these data, the achieved median OS of 9.9 months with the study treatment appears encouraging.
Side-effects included mainly fatigue, hematologic, gastrointestinal and neurologic toxicities as expected based on the carboplatin-paclitaxel backbone. Neither an increased severity of these chemotherapy-associated adverse events nor a significant toxicity attributable to everolimus was noted. Typical everolimus-related adverse events, like stomatitis, rash and ocular problems occurred only in a minority of patients (<15%) and were exclusively of grade 1-2. Thus, this study did not point to any undue safety risk when adding everolimus to carboplatin and paclitaxel.
Pretreatment NSE levels correlate with tumor burden and have prognostic value in operable LCNEC [29] . On the other hand, minimal induced NSE values during the study reflect the response to treatment and represent an independent prognostic factor in SCLC [30] . In our pure stage IV LCNEC patient cohort, PFS and OS were inversely associated with minimal induced (P ¼ 0.0114 and P ¼ 0.0003, respectively), but not with baseline NSE values. Thus, among patients with already disseminated LCNEC, biological characteristics of the tumor and response to treatment probably become more important for clinical outcome than initial tumor mass per se.
Based on the experience with other advanced cancers and targeted therapies, the benefit from novel compounds is mostly seen in patients with tumors bearing a suitable molecular profile rather than in unselected populations [31] . The same also applies to metastatic NSCLC [32] . Thus, it will be important to explore if mutations or other molecular alterations of the PI3K/AKT/ mTOR pathway are predictive biomarkers for the benefit of LCNEC patients from everolimus and could be used for patient selection, as has recently been shown in breast [33, 34] and renal cancer [35] . In addition, given the immunomodulatory properties of everolimus [18] , the increasingly recognized importance of the immune system for treatment response in lung cancer patients [19] and the broadening indications of immunotherapy [21] , it will be interesting to examine the role of immunologic parameters in this setting.
In summary, the present study shows that everolimus in combination with chemotherapy is a well-tolerated and effective firstline treatment for patients with metastatic LCNEC. Molecular studies could permit a tailored application to selected patients leading to improved outcomes.
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